IceCure Medical Ltd (NASDAQ:ICCM) Q1 2024 Earnings Conference Call May 28, 2024 11:00 AM ET

Company Participants

Michael Polyviou - Investor Relations
Eyal Shamir - Chief Executive Officer
Tlalit Bussi Tel-Tzure - VP, Business Development & Global Marketing
Ronen Tsimerman - Chief Financial Officer & Chief Operating Officer

Conference Call Participants

Kemp Dolliver - Brookline Capital Markets
Anthony Vendetti - Maxim Group
Ben Haynor - Lake Street Capital Markets
Yi Chen - H.C. Wainwright

Operator

Good morning, and thank you for standing by. Currently, all participants are in a listen-only mode. After management's discussion, there will be a question-and-answer session. Please be advised that today's conference call is being recorded.

I would now like to turn the conference over to Michael Polyviou. Please go ahead.

Michael Polyviou

Thank you, Yoni, and welcome to IceCure Medical's conference call to review the financial results for the three months ended March 31, 2024, and provide an update on recent operational highlights. You may refer to the earnings press release that we issued earlier this morning.

Participating on today's call are IceCure Medical's CEO, Eyal Shamir; CFO and COO, Ronen Tsimerman; and VP of Business Development and Global Marketing, Tlalit Bussi Tel-Tzure.

Before we begin, I will now take a moment to read the statement about forward-looking statements. This call and the question-and-answer session that follows it, contain forward-looking statements within the meaning of the safe public provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Words such as expects, anticipates, intends, plans, believes, seeks, estimates and similar expressions or variations of such words are intended to identify forward-looking statements.

For example, we are using forward-looking statements in this presentation when we discuss the achievements we expect to accomplish as we continue to advance our growth strategy and sales goals, our positioning to make significant commercial advances in key markets, the pursuit of regulatory approvals in various jurisdictions, including the expectation that cryoablation for breast cancer will be available to women in the U.S. this year, our expansion of clinical applications, including continued adoption of ProSense for many indications, potential market adoption and future sales of IceCure's minimal invasive cryoablation technology, advancing regulatory commercial strategies that we expect to continue positive response from the medical community as our commercial footprint expands and that a positive regulatory outcome in the U.S. for breast cancer will boost commercial traction for the treatment of breast cancer treatment through cryoablation. Because such statements yield future events and are based on IceCure's current expectations, they are subject to risks -- various risks and uncertainties and actual results, performance or achievements of IceCure could differ materially from those described in or implied by the statements during this call.